OGD2 Pharma SAS:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:OGD2 Pharma SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11029
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OGD2 Pharma SAS (OGD2 Pharma) is an independent pre-clinical stage biotechnology company that researches, develops and commercializes cancer immunotherapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2). The company pipeline product portfolio includes OGD201, a humanized monoclonal antibody for neuroblastoma; chimeric antigen receptors (CAR); antibody drug conjugates; blood test, in vivo imaging, and in vitro diagnostics products. OGD2 Pharma’s products also find application in the treatment of sarcoma, glioblastoma, melanoma, and breast cancer, and others. The company works in collaboration with academic institutions and industrial partners for developing innovative immunotherapies targeting O-acetylated-GD2 in cancer therapy. OGD2 Pharma is headquartered in Nantes, France.

OGD2 Pharma SAS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OGD2 Pharma SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
OGD2 Pharma Enters into Partnership Agreement with University Hospital Zurich 10
OGD2 Pharma Enters into Agreement with Syndivia 11
OGD2 Pharma Enters into Agreement with Green Cross LabCell 12
OGD2 Pharma SAS – Key Competitors 13
OGD2 Pharma SAS – Key Employees 14
OGD2 Pharma SAS – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Key Facts 2
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OGD2 Pharma SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OGD2 Pharma SAS, Deals By Therapy Area, 2012 to YTD 2018 8
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
OGD2 Pharma Enters into Partnership Agreement with University Hospital Zurich 10
OGD2 Pharma Enters into Agreement with Syndivia 11
OGD2 Pharma Enters into Agreement with Green Cross LabCell 12
OGD2 Pharma SAS, Key Competitors 13
OGD2 Pharma SAS, Key Employees 14

List of Figures
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OGD2 Pharma SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[OGD2 Pharma SAS:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • WEX Inc (WEX):企業の財務・戦略的SWOT分析
    WEX Inc (WEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Concert Pharmaceuticals Inc (CNCE):製薬・医療:M&Aディール及び事業提携情報
    Summary Concert Pharmaceuticals Inc (Concert Pharmaceuticals) is a clinical stage biotechnology company which discovers and develops small molecule drugs. The company develops its products using its deuterated chemical entity (DCE) platform to develop novel therapeutics for autoimmune and inflammato …
  • Seres Therapeutics Inc (MCRB):製薬・医療:M&Aディール及び事業提携情報
    Summary Seres Therapeutics Inc (Seres), is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company’ …
  • Genexine Inc (095700):製薬・医療:M&Aディール及び事業提携情報
    Summary Genexine Inc (Genexine), formerly Genexine Co Ltd is a clinical stage biotechnology company that develops and commercialize immunotherapeutics and next generation novel long-acting biologics. The company develops therapeutic vaccines for incurable diseases and next-generation antibody fusion …
  • Norgine BV:企業の戦略的SWOT分析
    Norgine BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Avantis Medical Systems Inc-医療機器分野:企業M&A・提携分析
    Summary Avantis Medical Systems Inc (AMS) is a medical device company that provides visualization technology solutions. The company provides products such as single camera colonoscopy devices and third eye panoramic devices. Its third eye panoramic devices provide two side-viewing cameras supplement …
  • Network Rail Limited:企業の戦略・SWOT・財務情報
    Network Rail Limited - Strategy, SWOT and Corporate Finance Report Summary Network Rail Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • 3M Company:企業の戦略・SWOT・財務分析
    3M Company - Strategy, SWOT and Corporate Finance Report Summary 3M Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Honkarakenne Oyj (HONBS):企業の財務・戦略的SWOT分析
    Honkarakenne Oyj (HONBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Kinnov Therapeutics SAS-製薬・医療分野:企業M&A・提携分析
    Summary Kinnov Therapeutics SAS (Kinnov) is a research and development company that discovers and develops therapies against addiction. The company’s pipeline product include KT-110, a pharmaceutical composition used as a therapy for addiction diseases. Its antagonist of alpha1-adrenergic receptors …
  • Greencore Group Plc:企業の戦略・SWOT・財務情報
    Greencore Group Plc - Strategy, SWOT and Corporate Finance Report Summary Greencore Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • UGI Corp (UGI):石油・ガス:M&Aディール及び事業提携情報
    Summary UGI Corp (UGI) is a holding company providing energy products and services. Through subsidiaries, the company stores, transports, distributes and markets energy products and related services. It distributes propane and butane both domestically and internationally and provides natural gas and …
  • Newfield Exploration Company (NFX):石油・ガス:M&Aディール及び事業提携情報
    Summary Newfield Exploration Co (Newfield) is an independent upstream company. The company focuses on onshore large scale, liquids-rich resource plays. Its domestic assets are in the Anadarko and Arkoma basins of Oklahoma, the Williston Basin of North Dakota and the Uinta Basin of Utah. The company …
  • Electronic Data Processing plc (EDP):企業の財務・戦略的SWOT分析
    Summary Electronic Data Processing plc (EDP), a subsidiary of Kerridge Commercial Systems Ltd, is a technology company that supplies computer services and solutions to merchants and distributors. The company offers hosting services, SaaS managed services, business continuity, service level agreement …
  • Nerviano Medical Sciences Srl:製薬・医療:M&Aディール及び事業提携情報
    Summary Nerviano Medical Sciences Srl (NMS) is a drug development company that discovers and develops novel anticancer drugs. The company's pipeline products include anticancer compounds such as Danusertib, Encorafenib, Entrectinib, ADC Payload programs, PARP1 program, NMS-088, Brostallicin, Milcicl …
  • Wolters Kluwer N.V. (WKL):企業の財務・戦略的SWOT分析
    Wolters Kluwer N.V. (WKL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BioRestorative Therapies Inc (BRTX):企業の財務・戦略的SWOT分析
    Summary BioRestorative Therapies Inc (BRT), formerly Stem Cell Assurance Inc is a developer of therapeutic products and medical therapies. The company performs stem cell programs which include brtxDISC and ThermoStem. brtxDISC,a lead therapeutic product, is designed to offer a non-surgical treatment …
  • Lonestar Resources US Inc (LONE):石油・ガス:M&Aディール及び事業提携情報
    Summary Lonestar Resources US Inc (Lonestar) is an independent oil and gas company that focuses on acquisition, exploration, development and production of oil and natural gas resources. Lonestar holds majority of the working interests in its properties and manages activities related to designing and …
  • Torm Plc (TRMD A):企業の財務・戦略的SWOT分析
    Torm Plc (TRMD A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Odakyu Electric Railway:企業の戦略・SWOT・財務分析
    Odakyu Electric Railway - Strategy, SWOT and Corporate Finance Report Summary Odakyu Electric Railway - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆